enGene Therapeutics Inc. (ENGN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$81.5M
Cash & Equivalents
$28.9M
Quarterly Burn Rate
8 mo
Est. Cash Runway
$115M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (1)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | PHASE2 | Recruiting | 350 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.